RS
ADCT icon

R Squared’s ADC Therapeutics ADCT Stock Holding History

R Squared’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Buy
13,926
+3,807
+38% +$11.1K 0.01% 499
2026
Q1 		$37.9K Buy
+10,119
New +$39.9K 0.02% 433
2025
Q4 		– Sell
-14,714
Closed -$58.9K – 516
2025
Q3 		$58.9K Buy
+14,714
New +$46.4K 0.03% 479

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

R Squared's ADCT Position: Q2 2026 in Review

R Squared increased its ADC Therapeutics (ADCT) stake by 38% in Q2 2026, buying an estimated $11.1K and bringing the position to 13,926 shares worth $14.9K. The position accounts for 0.01% of the portfolio, ranked #499.

R Squared first reported a position in ADCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $58.9K in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • R Squared held 13,926 shares of ADC Therapeutics worth $14.9K as of Q2 2026.
  • R Squared bought 3,807 ADC Therapeutics shares in Q2 2026, an estimated $11.1K.
  • ADC Therapeutics made up 0.01% of R Squared's portfolio in Q2 2026, its #499 holding.
  • R Squared first reported a position in ADC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • R Squared's ADC Therapeutics position peaked at $58.9K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.